RUBINSTEIN JULIE 4

What Happened
Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies (ADPT), received an award of 81,250 shares on March 4, 2026. The Form 4 reports the acquisition as an award/grant (transaction code A) at a reported price of $0.00 per share, which indicates a compensation grant (e.g., restricted stock or RSUs) rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-04 (reported on Form 4 filed 2026-03-06). Filing appears timely (filed within the 2-business-day window).
• Transaction type/code: Award/Grant (A). Reported price: $0.00 per share.
• Shares acquired: 81,250. Monetary value is not stated in the filing (market value would depend on ADPT's share price at grant).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes/conditions: None listed in the excerpt provided (check the full Form 4 for vesting schedule or restrictions).

Context
Grants/awards are typically part of executive compensation and do not directly indicate buying or selling sentiment. They often carry vesting conditions or restrictions; check the full filing or company proxy for vesting and tax-withholding details. For retail investors, purchases (P) are often more informative about personal conviction than compensation awards (A).